
NETRIS Pharma to Present Clinical Results of NP137 in Combination with Immune Checkpoint Inhibitors at ESMO 2025
Primary efficacy endpoint met in secondary refractory patients LYON, FRANCE, October 19, 2025 /EINPresswire.com/ -- NETRIS Pharma, a clinical-stage biotechnology company pioneering novel therapies targeting Netrin-1 to overcome resistance to …